GLUCO RX LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +9.1%

  £39,934,095 → £43,568,942

• Cash

  +11%

  £4,098,537 → £4,551,058

• Net assets

  +15%

  £90,508,590 → £104,069,697

• Employees

  +7.1%

  99 → 106

  highest in 3 filed years

• Operating profit

  +6%

  £13,835,442 → £14,666,342

• Profit before tax

  -1.9%

  £16,425,321 → £16,120,783

• Wages

  +12.5%

  £3,692,439 → £4,153,816

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Cheesmans

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and parent company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Group structure

1. GLUCO RX LIMITED · parent
   1. GlucoRX Technologies Limited 100% · Scotland
   2. Borg Pharma Limited 100%
   3. Pharmacy Link Limited 100%
   4. Microvisk Technologies Limited 100%
   5. Microvisk Limited 100%
   6. Microvisk Technologies International Limited 100%
   7. Conker PJ Limited 100%
   8. Gluco RX Healthcare Private Limited 100% · India
   9. Gluco RX Europe Limited 100% · Ireland

Significant events

• “Expansion of Portfolio: Broadening offerings in diabetes and other therapeutic areas, including cardiovascular and pain management.”
• “Globalisation Strategy: Transitioning from a UK-centric model to a global healthcare provider, leveraging success in the UK to penetrate international markets.”
• “R&D Innovation: Investing in ground breaking, non-invasive technologies and multiparameter monitoring systems.”
• “Phase 1: India (Operational): GlucoRx has already commenced operations in India through GlucoRx Healthcare Private Limited, based in Mumbai.”
• “Phase 2: MENA Region (Upcoming): Building on the momentum in India, the company is preparing to enter the Middle East and North Africa (MENA) region.”
• “Phase 3: Australasia (Future Expansion): The final stage of the current globalisation roadmap involves expanding into Australasia.”
• “Phase 4: With our own patented new products, we shall be entering into the lucrative UK, Europe and USA markets.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.